Diabetics and drug-eluting stents

Boston Scientific Corporation has announced results from a pooled analysis of patients from its TAXUS IV and TAXUS V randomised clinical trials to compare the safety and efficacy of the TAXUS Express Paclitaxel-Eluting Coronary Stent System in diabetic versus non-diabetic patients.

 The company reports that the results demonstrate that despite the known increased rates of mortality and restenosis for diabetics versus non-diabetics in patients with cardiovascular disease, the TAXUS Stent had comparable levels of late loss and target lesion revascularisation (TLR) across these patient populations. ‘The study also showed no significant differences in target vessel revascularisation (TVR), stent thrombosis, or myocardial infarction (MI), after adjustments were made for differences in other baseline characteristics between patients with or without diabetes.’ Analysis of the data was presented by Gregg W Stone MD, of the Columbia University Medical Centre, New York, at the SCAI Annual Scientific Sessions in Partnership with the ACC/i2 Summit in Chicago.
The pooled analysis included angiographic outcomes at nine months and clinical outcomes at three years among 338 diabetic patients and 901 non-diabetic patients treated with the TAXUS Stent from the TAXUS IV and V clinical trials. Nine-month angiographic outcomes showed equivalent in-segment late loss (0.27mm vs. 0.31mm, p=0.28) and binary restenosis (14.3% vs. 15.1%, p=0.83) in diabetics and non-diabetics, respectively.
 ‘The TAXUS IV/V diabetic subset data indicated that the TAXUS Stent mitigated the impact of diabetes as a risk factor for restenosis following stenting procedures in the patients studied,’ Dr Stone said. ‘Diabetic patients treated with TAXUS Stents compared with bare-metal stents had significantly improved event-free survival, particularly important in high-risk patients with diabetes.’

30.04.2008

Read all latest stories

Related articles

Photo

Sex differences

Cardiovascular risks may be worse for women’s cognition

New study results show that though men are more likely to have heart conditions, the impact on their memory and thinking skills is lower.

Photo

Cardiovascular disease prevention

Why a good night's sleep can save your heart

In a new study, researchers at Lund University and Uppsala University have seen a clear connection between how long a person sleeps and a number of biomarkers linked to cardiometabolic diseases such…

Photo

Obesity, heart disease, diabetes

Are NCD not so "non-communicable" after all?

Diseases such as cardiovascular diseases, cancer or certain lung diseases are among the most common non-natural causes of death today and account for about 70 percent of deaths worldwide. They are…

Related products

Alsachim – Dosinaco anticoagulant reagent kit (RUO)

Clinical Chemistry

Alsachim – Dosinaco anticoagulant reagent kit (RUO)

Alsachim, a Shimadzu Group Company
Beckman Coulter – HbA1c Advanced

Clinical Chemistry

Beckman Coulter – HbA1c Advanced

Beckman Coulter Diagnostics
Fujifilm Wako – Autokit Total Ketone Bodies Assay

Clinical Chemistry

Fujifilm Wako – Autokit Total Ketone Bodies Assay

FUJIFILM Wako Chemicals Europe GmbH
Lifotronic - FA-160 Immunofluorescence Analyzer

Immunoassays

Lifotronic - FA-160 Immunofluorescence Analyzer

Lifotronic Technology Co., Ltd
Subscribe to Newsletter